A Phase II, Double-Blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC).
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Vandetanib (Primary) ; Docetaxel; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004144).
- 14 Apr 2009 Actual end date changed from Nov 2006 to Sep 2008 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History